A Meta-Analysis and Systematic Review of the Relative Efficacy and Safety of Treatment With Statins for Assessing Cardiovascular Risk: Comparing ApoB, Non-HDL-C, and LDL-C

This meta-analysis and systematic review pooled data from major statin clinical trials — totaling 233,455 patients — to directly compare ApoB, non-HDL-C, and LDL-C as predictors of cardiovascular event risk and treatment benefit.

ApoB was a stronger predictor of residual cardiovascular risk than non-HDL-C, which in turn outperformed LDL-C. The hierarchy held consistently across both on-treatment risk prediction (who develops events despite statin therapy) and absolute risk reduction calculations. When all three measures were concordant, they predicted similarly. When discordant — which occurred in 20–30% of patients — ApoB most accurately identified who experienced cardiovascular events. The performance gap was largest in patients with high triglycerides and features of insulin resistance.

This was among the first large-scale meta-analyses to formally establish the ApoB > non-HDL-C > LDL-C hierarchy using clinical trial endpoints rather than epidemiological associations. With n=233,455 from landmark randomized trials, the statistical power to detect the ordering is substantial, and the findings are consistent with subsequent independent analyses.

The practical implication is that current LDL-C–based guidelines may systematically leave residual risk on the table in a substantial patient fraction. Measuring ApoB — particularly in high-triglyceride and metabolic syndrome patients — would reclassify a clinically meaningful proportion into higher-risk categories warranting more aggressive treatment.

We rate the evidence strong. A large and methodologically rigorous meta-analysis across 233,455 statin trial participants formally establishing that ApoB outperforms non-HDL-C which outperforms LDL-C as a cardiovascular risk marker — foundational evidence for the ApoB hierarchy in lipid risk stratification.